Retinal Vein Occlusion Market Size and Forecast 2024-2033|Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Novartis AG

Overview and Scope

Retinal vein occlusion (RVO) is a medical condition that occurs when a blockage or obstruction in the veins carries blood away from the retina, the light-sensitive tissue at the back of the eye. (RVO) can be avoided by preventing other blood vessel illnesses that raise the risk of RVO. This can be controlled by consuming a low-fat diet, regular exercise and maintaining a healthy weight.

Sizing and Forecast

The retinal vein occlusion market size has grown rapidly in recent years. It will grow from $13.79 billion in 2023 to $15.43 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to aging population, advancements in diagnostic imaging, pharmaceutical developments, increased diabetes prevalence.

The retinal vein occlusion market size is expected to see rapid growth in the next few years. It will grow to $23.08 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to innovative treatment approaches, telemedicine and remote monitoring, personalized medicine, regulatory approvals. Major trends in the forecast period include non-invasive treatment options, gene therapy breakthroughs, patient-centric care, digital health tools.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-global-market-report

Segmentation & Regional Insights

The retinal vein occlusion market covered in this report is segmented –

1) By Type: Branch Retinal Artery Occlusion; Central Retinal Vein Occlusion

2) By Condition: Non-Ischemic; Ischemic

3) By Diagnosis: Optical Coherence Tomography; Fundoscopic Examination; Fluorescein Angiography

4) By Treatment: Antivascular Endothelial Growth Factor; Corticosteroid Drugs; Laser Retinal Photocoagulation

5) By End User: Hospitals And Clinics; Research And Academics Centers; Other End-Users

North America was the largest region in the retinal vein occlusion market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in retinal vein occlusion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13058&type=smp

Major Driver Impacting Market Growth

An increase in the prevalence of eye disorders is expected to propel the growth of the ocular drug delivery market going forward. Eye disorders refer to a wide range of conditions that affect the eyes, vision, or the structures surrounding the eyes. The increased incidence of renal vein occlusion drives growth in the renal vein occlusion market, fostering demand for innovative diagnostics and treatments to address this condition. For instance, in March 2023, according to the World Health Organization, a Switzerland-based United Nations agency, globally, 2.2 billion people will have a near- or far-sighted impairment, according to estimates, cataracts (94 million) and uncorrected refractive problems (88.4 million) are the main causes of visual loss or impaired vision. In addition, glaucoma (7.7 million cases), corneal opacities (4.2 million cases), diabetic retinopathy (3.9 million cases) and trachoma (2 million cases) are the other common causes of vision loss. Therefore, the increasing prevalence of eye disorders will drive the retinal vein occlusion market.

Key Industry Players

Major players in the retinal vein occlusion market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Amgen Inc., Allergan PLC, Regeneron Pharmaceuticals Inc., Biogen Idec Inc., Vertex Pharmaceuticals Inc., Bausch Health Companies Inc., Carl Zeiss AG, Santen Pharmaceutical Co. Ltd., Lumenis Ltd., Coherus Biosciences Inc., Genentech Inc., Topcon Corporation, Nidek Co. Ltd., IRIDEX Corporation, Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., Ellex Medical Lasers Ltd., Adverum Biotechnologies Inc., Avik Pharmaceutical Limited (Avik), Outlook Therapeutics Inc., Annexin Pharmaceuticals AB, Ingenia Therapeutics Inc.

The retinal vein occlusion market report table of contents includes:

1. Executive Summary

2. Retinal Vein Occlusion Market Characteristics

3. Retinal Vein Occlusion Market Trends And Strategies

4. Retinal Vein Occlusion Market – Macro Economic Scenario

5. Global Retinal Vein Occlusion Market Size and Growth

26. South America Retinal Vein Occlusion Market

27. Brazil Retinal Vein Occlusion Market

28. Middle East Retinal Vein Occlusion Market

29. Africa Retinal Vein Occlusion Market

30. Retinal Vein Occlusion Market Competitive Landscape And Company Profiles

Top Major Players: